Odyssey Therapeutics Inc. Common Stock
Financials
Valuation Metrics
Odyssey Therapeutics Inc. Common Stock's Market Cap is $953M. Ranked #2455 of 3,115 in US market (top 79%), #1009 of 1,472 on NASDAQ (top 69%) by Market Cap.
Investment Metrics(as of 2026-10-29)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $953M | US#2,455/3,115 |
| Revenue | $3M | US#2,833/3,115 |
| Net Income | $-149M | US—/3,115 |
| Total Assets | $270M | US#2,928/3,115 |
| Net Assets | $-488M | US#3,011/3,115 |
| Employees | 100 | US#2,618/3,115 |
| Value | ||
| P/S | 320.23x | US#2,967/3,115 |
| FCF Yield | -13.71% | US—/3,115 |
| Profitability | ||
| ROA | -55.10% | US#2,999/3,115 |
| Op. Margin | -5415.19% | US#2,837/3,115 |
| Financial Health | ||
| Total Debt | $27M | US#2,701/3,115 |
| FCF | $-131M | US#2,691/3,115 |
| Cash | $42M | US#2,647/3,115 |
| Current Ratio | 7.20x | US#344/3,115 |
| Performance | ||
| 1M Return | -11.63% | US#2,522/3,115 |
| From 52W High | -31.74% | US#2,085/3,115 |
| 1Y MDD | -42.28% | US#2,041/3,115 |
| Trading | ||
| Volume | 209,998 shares | US#2,656/3,115 |
| Trading Value | $4M | US#2,729/3,115 |
| Per Share | ||
| EPS | $-3.09 | US—/3,115 |
| BPS | $-10.16 | US—/3,115 |
Company Info
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.